Therapies for Hepatitis B Virus: Current Status and Future Possibilities

  • Paul Martin
  • Lawrence S. Friedman
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 312)

Abstract

On a world-wide basis the hepatitis B virus (HBV) is the most significant viral pathogen affecting man; several hundred million people are infected. Although the chief burden of illness is felt in certain areas such as the Far East and sub-Saharan Africa, HBV is also a major cause of morbidity and mortality in the United States (1). Estimates by the Centers for Disease Control suggest that there are more than three hundred thousand new cases of acute hepatitis B in the United States every year, with four thousand deaths due to cirrhosis and one thousand deaths due to hepatocellular carcinoma annually (2). Approximately 0.5% of the United States population is chronically infected with HBV, in contrast to 20% of the population in endemic areas such as the Far East and sub-Saharan Africa.

Keywords

Chronic Hepatitis Chronic Active Hepatitis Hepatitis Delta Virus Chronic Persistent Hepatitis Adenine Arabinoside 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Hoofnagle, J.H., Chronic hepatitis B, N. Engl. J. Med. 323:337–339 (1990).CrossRefPubMedGoogle Scholar
  2. 2.
    Aach, R.D., The treatment of chronic type B viral hepatitis, Ann. Intern. Med. 109:89–91 (1988).PubMedGoogle Scholar
  3. 3.
    Seeff, L.B., Koff, R.S., Evolving concepts of the clinical and serological consequences of hepatitis B virus infection, Sem. Liv. Dis. 6:11–22 (1986).CrossRefGoogle Scholar
  4. 4.
    Beasley, R.P., Hwang, E.Y., Lin, C-C., Chien, C-S., Hepatocellular carcinoma and hepatitis B virus, Lancet ii:1129–1133 (1981).CrossRefGoogle Scholar
  5. 5.
    Carman, W.F., Jacyn, M.R., Hadziyannis, S., Karayiannis P., McGarney M.J., Makris A., Thomas H.C., Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection, Lancet ii: 88–591 (1989).Google Scholar
  6. 6.
    Kaneko, S., Miller, R.H., Feinstein, S.M., Unura M., Kobayashi K., Hatlor N., Detection of serum hepatitis B virus DNA in patients with chronic hepatitis using the polymerase chain assay, Proc. Natl. Acad. Sci. USA 86:312–316 (1989).CrossRefPubMedGoogle Scholar
  7. 7.
    Weissberg, J.I., Andres, L.J., Smith, C.I., Weick S., Nichols J.E., Garcia G., Robinson W., Merigan T., Gregory P., Survival in chronic hepatitis B: an analysis of 379 patients, Ann. Intern. Med. 101:613–616 (1984).PubMedGoogle Scholar
  8. 8.
    Kuhns, M., Mason, A., McNamara, A., Campbell, C., Perrillo R.P., Polymerase chain reaction in the determination of HBV DNA after HBsAg clearance in chronic hepatitis B, Hepatology 12:904 (1990).Google Scholar
  9. 9.
    Hoofnagle, J.H., Peters, M., Mullen, K.D., Jones D.B., Rustyi V., Di Bisceglie A., Itallahan C., Park Y., Meschievitz C., Jones E.A., Randomized controlled trial of recombinant human alpha interferon in patients with chronic hepatitis B, Gastroenterology 95:1318–1325 (1988).PubMedGoogle Scholar
  10. 10.
    Perillo, R.P., Regenstein, F.G., Peters, M.G., Deschryver-Kecskemeti K., Bodicky C., Campbell C.R., Kuhns M.C., Prednisone withdrawal followed by recombinant alpha interferon in the treatment of chronic type B hepatitis: a randomized, controlled trial, Ann. Intern. Med. 109:95–100 (1988).Google Scholar
  11. 11.
    Perillo, R.P., Schiff, E.R., Davis, G.L., Bodenheimer H.C. Jr., Lindsay K., Pagne J., Dienstag J.C., O’brien C., Tamburro C., Jacobson I.N., Sampliner R., Feit D., Lefkowitch J., Kohns M., Meschievitz C., Sanghri B., Albrecht J., Gibas A., A randomized controlled trial of interferon alpha-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B, N. Engl. J. Med. 323:295–301 (1990).CrossRefGoogle Scholar
  12. 12.
    Lam, K.L., Lai, C.L., Trepo, C., Wu, P.C., Deleterious effect of prednisone in HBsAg-positive chronic acute hepatitis, N. Engl. J. Med. 304:380–386 (1981).CrossRefPubMedGoogle Scholar
  13. 13.
    Hoofnagle, J.H., Davis, G.L., Pappas, S.C., Hanson R., Peters M. Avigan M., Waggoner J., Jones E.A., Seeff L.B., A short course of prednisone in chronic type B hepatitis: report of a randomized, double-blind, placebo-controlled trial, Ann. Intern. Med. 104:12–17 (1986).PubMedGoogle Scholar
  14. 14.
    Garcia, G., Smith C.C., Weissberg, J.I., Eisenberg M., Bissett J., Nair P.V., Mastre B., Rosno S., Roskamp D., Waterman K., Pollard R.B., Tong M.J., Brown B.W., Robinson W.S., Gregory P.B., Merigan T.C., Adenine arabinoside monophosphate (vidarabine phosphate) in combination with human leukocyte interferon: a randomized, double-blind, placebo-controlled trial, Ann. Intern. Med. 107:278–285 (1987).PubMedGoogle Scholar
  15. 15.
    Hoofnagle, J.H., Hanson, R.G., Minuk, G.Y., Pappas S.C., Schafer D.F., Dusheiko G.M., Straus S.E., Popper H., Jones E.A., Randomized controlled trial of adenine arabinoside monophosphate for chronic type B hepatitis, Gastroenterology 86:150–157 (1984).PubMedGoogle Scholar
  16. 16.
    Alexander, G.J.M., Fagan, E.A., Hagarty, J.E., Yeo J., Eddleston A.C., Williams R., Controlled clinical trial of acyclovir in chronic hepatitis B virus infection, J. Med. Virol. 21:81–87 (1987).CrossRefPubMedGoogle Scholar
  17. 17.
    Kakumu, S., Fuju, A., Yoshioka, K., Tahara H., Ohtani Y., Hirofuji H., Murase K., Aoi, T., Pilot study of recombinant human interleukin-2 for chronic type B hepatitis, Hepatology 8:487–492 (1988).CrossRefPubMedGoogle Scholar
  18. 18.
    Peters, M, Immunological aspects of antiviral therapy, Springer Sem. Immunopathol. 12:47–56 (1990).Google Scholar
  19. 19.
    Davis, G.L., Hoofnagle, J.H., Interferon and viral hepatitis, Hepatology 5:1038–1041(1986).Google Scholar
  20. 20.
    Di Bisceglie, A.M., Rustgi, V.K., Kassianides, C., Lisker-Melman M., Park Y., Waggoner J.G., Hoofnagle J., Therapy of chronic hepatitis B with recombinant human alpha and gamma interferon, Hepatology 11:266–270 (1990).CrossRefPubMedGoogle Scholar
  21. 21.
    Greenberg, H.B., Pollard, R.B., Lutwick, L.I., Gregory P.B., Robinson W.S., Merigan, T.C., Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis, N. Engl. J. Med. 295:517–522 (1976).CrossRefPubMedGoogle Scholar
  22. 22.
    Perrillo, R.P., Interferon therapy of hepatitis B infection, Sem. Liv. Dis. 9:240–248 (1989).CrossRefGoogle Scholar
  23. 23.
    Scully, L.J., Shein, R., Korayiannis, P., McDonald J.A., Thomas H.C., Lymphoblastoid interferon therapy of chronic HBV infection: a comparison of 12 vs. 24 weeks of thrice weekly treatment, J. Hepatol. 5:51–58 (1987).CrossRefPubMedGoogle Scholar
  24. 24.
    Lok, A.S.F., Lai, C.L., Wu, P.C., Lan J.Y., Leung E.K., Wong L.S., Treatment of chronic hepatitis B with interferon: experience in Asian patients, Sem. Liv. Dis. 9:249–253 (1989).CrossRefGoogle Scholar
  25. 25.
    Novick, D.M., Lok, A.S.F., Thomas, H.C., Diminished responsiveness of homosexual men to antiviral therapy for HBsAg-positive chronic liver disease, J. Hepatol. 1:29–35 (1984).CrossRefGoogle Scholar
  26. 26.
    McDonald, J.A., Caruso, L., Korayiannis, P., Scully L.J., Harris J.R.W., Forster G.E., Thomas H.C., Diminished responsiveness of male homosexual chronic hepatitis B virus carriers with HTLV-III antibodies to recombinant alpha-interferon, Hepatology 7:719–723 (1987).CrossRefPubMedGoogle Scholar
  27. 27.
    Davis, G.L., Interferon treatment of viral hepatitis in immunocompromised patients, Sem. Liv. Dis. 9:267–272 (1989).CrossRefGoogle Scholar
  28. 28.
    Mason, W.S., Taylor, J.M., Experimental systems for the study of hepadnavirus and hepatitis delta virus infection, Hepatology 9:635–645 (1989).CrossRefPubMedGoogle Scholar
  29. 29.
    Kassianides, C., Hoofnagle, J.H., Miller, R.H., Doo E., Fordi H., Broder S., Mitsuya H., Inhibition of duck hepatitis B virus replication by 2’,3’- dideoxycytidine: a potent inhibitor of reverse transcriptase, Gastroenterology 97:1275–1280 (1989).PubMedGoogle Scholar
  30. 30.
    Summers, J., Mason, W.S., Replication of the genome of a hepatitis B-like virus by reverse transcriptase of an RNA intermediate, Cell 29:403–415 (1982).CrossRefPubMedGoogle Scholar
  31. 31.
    Yarchoan, R., Mitsuya, H., Meyers, C.E., Broder, S., Clinical pharmacology of 3’-azido-2’3’-deoxythymidine (Zidovidine) and related dideoxynucleosides, N. Engl. J. Med. 321:726–738 (1989).CrossRefPubMedGoogle Scholar
  32. 32.
    Martin, P., Kassianides, C., Korenman, J.E., Hoofnagle J.H., Ford H., Broder S., Mitsuya H., 2’-3’-dideoxyinosine and dideoxyguanosine are potent inhibitors of hepadnaviruses in vivo, Gastroenterology 96:628 (1989).Google Scholar
  33. 33.
    Schalm, S.W., Heyfink, R.A., Van Burnes, H.R., De Man, R.A., Acyclovir enhances the antiviral effect of interferon in chronic hepatitis B, Lancet ii:358–360 (1985).CrossRefGoogle Scholar
  34. 34.
    Mutchick, M.G., Appelman, H.D., Chung, H.T., Aragone, E., Grupta, T.P., Cummings, G.D., Waggoner, J.G., Hoofnagle, J.M., Shiefritz, D.A. Thymosin treatment of chronic hepatitis B: A placebo-controlled pilot trial. Hepatology 14:409–415 (1991).CrossRefGoogle Scholar
  35. 35.
    Davis, G.L. Treatment of chronic hepatitis B, Hepatology 14:567–569 (1991).CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1992

Authors and Affiliations

  • Paul Martin
    • 1
  • Lawrence S. Friedman
    • 1
  1. 1.Division of Gastroenterology and HepatologyJefferson Medical CollegePhiladelphiaUSA

Personalised recommendations